Full Press Release Details
BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510.
BBIO
BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510
Key Takeaway: BridgeBio Announces Clinical Collaboration With Amgen To Study BBP-398, A Potentially Best-in-class SHP2 Inhibitor, In Combination With AMG 510
Price reaction · baseline $13.6 (2022-01-12 close) · hit after-hours · clean, no other BBIO news in the window
day 0 close · peak
-4.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis